DS-8201
-
【Product for Licensing】A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
ASCO Express: From “low expression” to “even lower expression”, the best-selling ADC enters the next level!
Following the FDA’s accelerated approval of Enhertu (trastuzumab deruxtecan, …
